Unknown PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT02630368

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX)

A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)

Sponsor: Fondation ARC

Conditions Breast Cancer Soft-tissue Sarcoma Solid Tumors

Interventions Avelumab and JX-594 and Cyclophosphamide Cyclophosphamide Cyclophosphamide and JX-594 Cyclophosphamide and JX-594 dose escalation

Updated 10 times since 2017 Last updated: Feb 1, 2022 Started: Sep 18, 2015 Primary completion: May 31, 2023 Completion: Nov 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Cancer and Soft-tissue Sarcoma, this trial is ongoing. The trial is conducted by Fondation ARC and has accumulated 10 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Dec 2024 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2022 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Jun 2022 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 5 earlier versions

Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

Status: Unknown Status → Recruiting
Oct 2020 — Nov 2020 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Oct 2020 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondation ARC
Institut Bergonié
Merck Sharp & Dohme LLC
National Cancer Institute, France
Transgene

Data source: Institut Bergonié

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bordeaux, France